Cargando…
Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
BACKGROUND: Efforts are underway to eliminate trachoma as a public health problem by 2020. Programmatic guidelines are based on clinical signs that correlate poorly with Chlamydia trachomatis (Ct) infection in post-treatment and low-endemicity settings. Age-specific seroprevalence of anti Ct Pgp3 an...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242428/ https://www.ncbi.nlm.nih.gov/pubmed/28099433 http://dx.doi.org/10.1371/journal.pntd.0005230 |
_version_ | 1782496329777283072 |
---|---|
author | Migchelsen, Stephanie J. Martin, Diana L. Southisombath, Khamphoua Turyaguma, Patrick Heggen, Anne Rubangakene, Peter Paul Joof, Hassan Makalo, Pateh Cooley, Gretchen Gwyn, Sarah Solomon, Anthony W. Holland, Martin J. Courtright, Paul Willis, Rebecca Alexander, Neal D. E. Mabey, David C. W. Roberts, Chrissy h. |
author_facet | Migchelsen, Stephanie J. Martin, Diana L. Southisombath, Khamphoua Turyaguma, Patrick Heggen, Anne Rubangakene, Peter Paul Joof, Hassan Makalo, Pateh Cooley, Gretchen Gwyn, Sarah Solomon, Anthony W. Holland, Martin J. Courtright, Paul Willis, Rebecca Alexander, Neal D. E. Mabey, David C. W. Roberts, Chrissy h. |
author_sort | Migchelsen, Stephanie J. |
collection | PubMed |
description | BACKGROUND: Efforts are underway to eliminate trachoma as a public health problem by 2020. Programmatic guidelines are based on clinical signs that correlate poorly with Chlamydia trachomatis (Ct) infection in post-treatment and low-endemicity settings. Age-specific seroprevalence of anti Ct Pgp3 antibodies has been proposed as an alternative indicator of the need for intervention. To standardise the use of these tools, it is necessary to develop an analytical approach that performs reproducibly both within and between studies. METHODOLOGY: Dried blood spots were collected in 2014 from children aged 1–9 years in Laos (n = 952) and Uganda (n = 2700) and from people aged 1–90 years in The Gambia (n = 1868). Anti-Pgp3 antibodies were detected by ELISA. A number of visual and statistical analytical approaches for defining serological status were compared. PRINCIPAL FINDINGS: Seroprevalence was estimated at 11.3% (Laos), 13.4% (Uganda) and 29.3% (The Gambia) by visual inspection of the inflection point. The expectation-maximisation algorithm estimated seroprevalence at 10.4% (Laos), 24.3% (Uganda) and 29.3% (The Gambia). Finite mixture model estimates were 15.6% (Laos), 17.1% (Uganda) and 26.2% (The Gambia). Receiver operating characteristic (ROC) curve analysis using a threshold calibrated against external reference specimens estimated the seroprevalence at 6.7% (Laos), 6.8% (Uganda) and 20.9% (The Gambia) when the threshold was set to optimise Youden’s J index. The ROC curve analysis was found to estimate seroprevalence at lower levels than estimates based on thresholds established using internal reference data. Thresholds defined using internal reference threshold methods did not vary substantially between population samples. CONCLUSIONS: Internally calibrated approaches to threshold specification are reproducible and consistent and thus have advantages over methods that require external calibrators. We propose that future serological analyses in trachoma use a finite mixture model or expectation-maximisation algorithm as a means of setting the threshold for ELISA data. This will facilitate standardisation and harmonisation between studies and eliminate the need to establish and maintain a global calibration standard. |
format | Online Article Text |
id | pubmed-5242428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-52424282017-02-06 Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies Migchelsen, Stephanie J. Martin, Diana L. Southisombath, Khamphoua Turyaguma, Patrick Heggen, Anne Rubangakene, Peter Paul Joof, Hassan Makalo, Pateh Cooley, Gretchen Gwyn, Sarah Solomon, Anthony W. Holland, Martin J. Courtright, Paul Willis, Rebecca Alexander, Neal D. E. Mabey, David C. W. Roberts, Chrissy h. PLoS Negl Trop Dis Research Article BACKGROUND: Efforts are underway to eliminate trachoma as a public health problem by 2020. Programmatic guidelines are based on clinical signs that correlate poorly with Chlamydia trachomatis (Ct) infection in post-treatment and low-endemicity settings. Age-specific seroprevalence of anti Ct Pgp3 antibodies has been proposed as an alternative indicator of the need for intervention. To standardise the use of these tools, it is necessary to develop an analytical approach that performs reproducibly both within and between studies. METHODOLOGY: Dried blood spots were collected in 2014 from children aged 1–9 years in Laos (n = 952) and Uganda (n = 2700) and from people aged 1–90 years in The Gambia (n = 1868). Anti-Pgp3 antibodies were detected by ELISA. A number of visual and statistical analytical approaches for defining serological status were compared. PRINCIPAL FINDINGS: Seroprevalence was estimated at 11.3% (Laos), 13.4% (Uganda) and 29.3% (The Gambia) by visual inspection of the inflection point. The expectation-maximisation algorithm estimated seroprevalence at 10.4% (Laos), 24.3% (Uganda) and 29.3% (The Gambia). Finite mixture model estimates were 15.6% (Laos), 17.1% (Uganda) and 26.2% (The Gambia). Receiver operating characteristic (ROC) curve analysis using a threshold calibrated against external reference specimens estimated the seroprevalence at 6.7% (Laos), 6.8% (Uganda) and 20.9% (The Gambia) when the threshold was set to optimise Youden’s J index. The ROC curve analysis was found to estimate seroprevalence at lower levels than estimates based on thresholds established using internal reference data. Thresholds defined using internal reference threshold methods did not vary substantially between population samples. CONCLUSIONS: Internally calibrated approaches to threshold specification are reproducible and consistent and thus have advantages over methods that require external calibrators. We propose that future serological analyses in trachoma use a finite mixture model or expectation-maximisation algorithm as a means of setting the threshold for ELISA data. This will facilitate standardisation and harmonisation between studies and eliminate the need to establish and maintain a global calibration standard. Public Library of Science 2017-01-18 /pmc/articles/PMC5242428/ /pubmed/28099433 http://dx.doi.org/10.1371/journal.pntd.0005230 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Migchelsen, Stephanie J. Martin, Diana L. Southisombath, Khamphoua Turyaguma, Patrick Heggen, Anne Rubangakene, Peter Paul Joof, Hassan Makalo, Pateh Cooley, Gretchen Gwyn, Sarah Solomon, Anthony W. Holland, Martin J. Courtright, Paul Willis, Rebecca Alexander, Neal D. E. Mabey, David C. W. Roberts, Chrissy h. Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies |
title | Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies |
title_full | Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies |
title_fullStr | Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies |
title_full_unstemmed | Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies |
title_short | Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies |
title_sort | defining seropositivity thresholds for use in trachoma elimination studies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242428/ https://www.ncbi.nlm.nih.gov/pubmed/28099433 http://dx.doi.org/10.1371/journal.pntd.0005230 |
work_keys_str_mv | AT migchelsenstephaniej definingseropositivitythresholdsforuseintrachomaeliminationstudies AT martindianal definingseropositivitythresholdsforuseintrachomaeliminationstudies AT southisombathkhamphoua definingseropositivitythresholdsforuseintrachomaeliminationstudies AT turyagumapatrick definingseropositivitythresholdsforuseintrachomaeliminationstudies AT heggenanne definingseropositivitythresholdsforuseintrachomaeliminationstudies AT rubangakenepeterpaul definingseropositivitythresholdsforuseintrachomaeliminationstudies AT joofhassan definingseropositivitythresholdsforuseintrachomaeliminationstudies AT makalopateh definingseropositivitythresholdsforuseintrachomaeliminationstudies AT cooleygretchen definingseropositivitythresholdsforuseintrachomaeliminationstudies AT gwynsarah definingseropositivitythresholdsforuseintrachomaeliminationstudies AT solomonanthonyw definingseropositivitythresholdsforuseintrachomaeliminationstudies AT hollandmartinj definingseropositivitythresholdsforuseintrachomaeliminationstudies AT courtrightpaul definingseropositivitythresholdsforuseintrachomaeliminationstudies AT willisrebecca definingseropositivitythresholdsforuseintrachomaeliminationstudies AT alexandernealde definingseropositivitythresholdsforuseintrachomaeliminationstudies AT mabeydavidcw definingseropositivitythresholdsforuseintrachomaeliminationstudies AT robertschrissyh definingseropositivitythresholdsforuseintrachomaeliminationstudies |